Physician profile

Brigitte Curtis

Child & Adolescent Psychiatry · Lubbock, TX

NPI 1225059967

$454.39

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$261.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alkermes, INC. $136.87 2023 Lybalvi
Teva Pharmaceuticals USA, INC. $73.98 2023 Austedo Xr
Abbvie INC. $56.75 2021-2023 Vraylar
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $50.75 2020-2023
Lundbeck LLC $44.22 2022-2023 Rexulti
Otsuka America Pharmaceutical, INC. $41.01 2019-2022
Ironshore Pharmaceuticals INC. $28.39 2022
Takeda Pharmaceuticals U.S.A., INC. $22.42 2019-2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brigitte Curtis

$454.39

in general payments reported 2019-2025

Years
2019-2023
Top company
Alkermes, INC.

https://glasscript.com/doctor/55412/brigitte-curtis

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.